European Journal of Nuclear Medicine and Molecular Imaging
identifcation of a new molecular subtype and association with
triple negative disease. Springerplus. 2012;1:22.
References
20. Jager NA, Westra J, Golestani R, van Dam GM, Low PS, Tio
RA, et al. Folate receptor-β imaging using 99mTc-folate to
explore distribution of polarized macrophage populations in
human atherosclerotic plaque. J Nucl Med. 2014;55:1945–51.
21. Müller A, Beck K, Rancic Z, Müller C, Fischer CR, Betzel T,
et al. Imaging atherosclerotic plaque infammation via folate
receptor targeting using a novel 18F-folate radiotracer. Mol
Imaging. 2014;13:1–11.
1. Libby P, Ridker PM, Hansson GK. Progress and chal-
lenges in translating the biology of atherosclerosis. Nature.
2011;473:317–25.
2. Shaw L, Chandrashekhar Y. Progress in cardiovascular imaging.
JACC Cardiovasc Imag. 2019;12:2589–610.
3. Nakahara T, Dweck MR, Narula N, Pisapia D, Narula J, Strauss
HW. Coronary artery calcifcation: from mechanism to molecular
imaging. JACC Cardiovasc Imag. 2017;10:582–93.
22. Xia W, Hilgenbrink AR, Matteson EL, Lockwood MB, Cheng
JX, Low PS. A functional folate receptor is induced during mac-
rophage activation and can be used to target drugs to activated
macrophages. Blood. 2009;113:438–46.
4. Lee SB, Park GM, Lee JY, Lee BU, Park JH, Kim BG, et al. Asso-
ciation between non-alcoholic fatty liver disease and subclinical
coronary atherosclerosis: an observational cohort study. J Hepatol.
2018;68:1018–24.
23. Williams JW, Giannarelli C, Rahman A, Randolph GJ, Kovacic
JC. Macrophage biology, classifcation, and phenotype in car-
diovascular disease: JACC macrophage in CVD series (part 1).
J Am Coll Cardiol. 2018;72:2166–80.
5. Sinn DH, Kang D, Chang Y, Ryu S, Gu S, Kim H, et al. Non-
alcoholic fatty liver disease and progression of coronary artery
calcium score: a retrospective cohort study. Gut. 2017;66:323–9.
6. Sinn DH, Cho SJ, Gu S, Seong D, Kang D, Kim H, et al. Persistent
nonalcoholic fatty liver disease increases risk for carotid athero-
sclerosis. Gastroenterology. 2017;66:323–9.
24. Werner RA, Thackeray JT, Diekmann J, Weiberg D, Bauersachs
J, Bengel FM. The changing face of nuclear cardiology: guiding
cardiovascular care toward molecular medicine. J Nucl Med.
2020;61:951–61.
7. Ma J, Hwang SJ, Pedley A, Massaro JM, Hofmann U, Chung RT,
et al. Bidirectional analysis between fatty liver and cardiovascular
disease risk factors. J Hepatol. 2017;66:390–7.
25. Paulos CM, Turk MJ, Breur GJ, Low PS. Folate receptor-medi-
ated targeting of therapeutic and imaging agents to activated
macrophages in rheumatoid arthritis. Adv Drug Deliv Rev.
2004;56:1205–17.
8. Makowski MR, Wiethof AJ, Blume U, Cuello F, Warley A,
Jansen CHP, et al. Assessment of atherosclerotic plaque burden
with an elastin-specifc magnetic resonance contrast agent. Nat
Med. 2011;17:383–8.
26. Silvola JMU, Li X, Virta J, Marjamäki P, Liljenbäck H, Hytönen
JP, et al. Aluminum fuoride-18 labeled folate enables in vivo
detection of atherosclerotic plaque infammation by positron
emission tomography. Sci Rep. 2018;8:9720.
9. Judenhofer MS, Wehrl HF, Newport DF, Catana C, Siegel SB,
Becker M, et al. Simultaneous PET-MRI: a new approach for func-
tional and morphological imaging. Nat Med. 2008;14:459–65.
10. Abele JT, Fung CI. Effect of hepatic steatosis on liver FDG
uptake measured in mean standard uptake values. Radiology.
2010;254:917–24.
27. Ayala-López W, Xia W, Varghese B, Low PS. Imaging of ather-
osclerosis in apoliprotein e knockout mice: targeting of a folate-
conjugated radiopharmaceutical to activated macrophages. J
Nucl Med. 2010;51:768–74.
11. Moon SH, Hong SP, Cho YS, Noh TS, Choi JY, Kim BT, et al.
Hepatic FDG uptake is associated with future cardiovascular
events in asymptomatic individuals with non-alcoholic fatty liver
disease. J Nucl Cardiol. 2015;24:892–9.
28. Jahandideh A, Uotila S, Stahle M, Virta J, Li XG, Kyto V, et al.
Folate receptor β-targeted PET imaging of macrophages in auto-
immune myocarditis. J Nucl Med. 2020;61:1643–9.
29. Guo Z, You L, Shi C, Song M, Gao M, Xu D, et al. Develop-
ment of a new FR-targeting agent 99mTc-HYNFA with improved
imaging contrast and comparison of multimerization and/or
PEGylation strategies for radio-folate modifcation. Mol Pharm.
2017;14:3780–8.
12. Lee HJ, Lee CH, Kim S, Hwang SY, Hong HC, Choi HY, et al.
Association between vascular infammation and non-alcoholic
fatty liver disease: analysis by 18F-fuorodeoxyglucose positron
emission tomography. Metabolism. 2017;67:72–9.
13. Daghem M, Bing R, Fayad ZA, Dweck MR. Noninvasive imaging
to assess atherosclerotic plaque composition and disease activ-
ity: coronary and carotid applications. JACC Cardiovasc Imag.
2020;13:1055–68.
30. Guo Z, Zhang P, Song M, Wu X, Liu C, Zhao Z, et al. Syn-
thesis and preliminary evaluation of novel 99mTc-labeled folate
derivative via click reaction for SPECT imaging. Appl Radiat
Isotopes. 2014;91:24–30.
14. Tabas I, Bornfeldt KE. Intracellular and intercellular aspects of
macrophage immunometabolism in atherosclerosis. Circ Res.
2020;126:1209–27.
31. Guo Z, Gao M, Song M, Shi C, Zhang P, Xu D, et al. Synthe-
sis and evaluation of 99mTc-labeled dimeric folic acid for FR-
targeting. Molecules. 2016;21:817–29.
15. Kazankov K, Jørgensen SMD, Thomsen KL, Møller HJ, Vilstrup
H, George J, et al. The role of macrophages in nonalcoholic fatty
liver disease and nonalcoholic steatohepatitis. Nat Rev Gastroen-
terol Hepatol. 2019;16:145–59.
32. Guo Z, Yang L, Chen M, Wen X, Liu H, Li J, et al. Molecular
imaging of advanced atherosclerotic plaques with folate recep-
tor-targeted 2D nanoprobes. Nano Res. 2019;13:173–82.
33. Lau J, Jacobson O, Niu G, Lin KS, Bѐnard F, Chen X. Bench
to bedside: albumin binders for improved cancer radioligand
therapies. Bioconjug Chem. 2019;30:487–502.
16. Park JW, Jeong G, Kim SJ, Kim MK, Park SM. Predictors
refecting the pathological severity of non-alcoholic fatty liver
disease: comprehensive study of clinical and immunohistochemi-
cal fndings in younger Asian patients. J Gastroenterol Hepatol.
2007;22:491–7.
34. Siwowska K, Haller S, Bortoli F, Benešová M, Groehn V, Bern-
hardt P, et al. Preclinical comparison of albumin-binding radi-
ofolates: impact of linker entities on the in vitro and in vivo
properties. Mol Pharm. 2017;14:523–32.
17. Kelemen LE. The role of folate receptor alpha in cancer develop-
ment, progression and treatment: cause, consequence or innocent
bystander? Int J Cancer. 2006;119:243–50.
35. Deberle LM, Benešová M, Umbricht CA, Borgna F, Büchler
M, Zhernosekov K, et al. Development of a new class of PSMA
radioligands comprising ibuprofen as an albumin-binding entity.
Theranostics. 2020;10:1678–93.
18. Shi H, Guo J, Li C, Wang Z. A current review of folate receptor
alpha as a potential tumor target in non-small-cell lung cancer.
Drug Des Devel Ther. 2015;9:4989–96.
36. Müller C, Struthers H, Winiger C, Zhernosekov K, Schibli R.
DOTA conjugate with an albumin-binding entity enables the
19. O’Shannessy DJ, Somers EB, Maltzman J, Smale R, Fu YS.
Folate receptor alpha (FRA) expression in breast cancer:
1 3